clinical trial · NCT06842186
A Phase 1 Study of WVE-007 in Adults Living With Overweight or Obesity
Obesity and OverweightWVE-007
brief summary
The purpose of this study is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of WVE-007 when administered subcutaneously (SC) as single ascending doses in adults who are affected by overweight or obesity.
started
Jan 31, 2025
primary completion
Oct 1, 2026
completion
Oct 1, 2026
last updated
Feb 10, 2026
official title
A Phase 1, Randomized, Double-blind, Placebo-controlled Study of Ascending Doses of WVE-007 to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Adults Living With Overweight or Obesity
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol